⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

COAG

Hemab Therapeutics Holdings, Inc.

Healthcare · Biotechnology

34.40USD

-0.4150 (-1.19%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on COAG.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
1)

Comparable Revenue

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)2024202520262027
FY——0.00.0
Q1————
Q2————
Q3——0.0—
Q4——0.0—
2)

Comparable Earnings Per Share

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)2024202520262027
FY——-3.11-2.55
Q1—-16.18-23.98—
Q2—-12.91-.800—
Q3——-.515—
Q4——-.570—

Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.

3)

Revenue to Profit Conversion

Revenue to net income

 

 

QuarterlyAnnual
Level
4)

Debt Level and Coverage

Debt level and coverage

 

 

QuarterlyAnnual
Debt